




29th **ECCMID**

**Amsterdam, Netherlands**  
13 – 16 April 2019

The congress of  **ESCMID**

### **P0399 Safety and immunogenicity of 2-dose Ebola vaccine regimen with Ad26.ZEBOV and MVA-BN-Filo in a phase II clinical trial in Europe (EBOVAC2)**

Rodolphe Thiebaut<sup>1</sup>, Matthew D Snape<sup>2</sup>, Neil Goldstein<sup>3</sup>, Cynthia Robinson<sup>3</sup>, Auguste Gaddah<sup>4</sup>, Viki Bockstal<sup>3</sup>, Odile Launay<sup>5</sup>, Jean-Daniel Lelievre<sup>6</sup>, Laura Richert<sup>1</sup>, Christine Betard<sup>1</sup>, Andrew Pollard<sup>2</sup>, Malick Gibani<sup>2</sup>, Elizabeth Clutterbuck\*<sup>2</sup>, Maarten Leyssen<sup>3</sup>, Kerstin Luhn<sup>3</sup>, Macaya Douoguih<sup>3</sup>

<sup>1</sup> Inserm U1219, and Euclid F-CRIN Clinical Trials Platform, Bordeaux, France, <sup>2</sup> Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom, <sup>3</sup> Janssen Vaccines & Prevention, Leiden, Netherlands, <sup>4</sup> Janssen Research & Development, Beerse, Belgium, <sup>5</sup> AP-HP, Inserm, F-CRIN I-REIVAC; AP-HP, CIC Cochin Pasteur, Hopital Cochin, Paris, France, <sup>6</sup> VRI, Inserm, UPEC and AP-HP, Hopital Mondor, Creteil, France

**Background:** The West African 2014–16 Ebola epidemic highlights the need for safe and effective Ebola vaccines. A heterologous Ebola vaccine regimen based on Ad26.ZEBOV (Ad26) and MVA-BN®-Filo (MVA) is in Phase 3 development.

Here we report results of a Phase 2 study (EBL2001) funded by the European Commission Innovative Medicines Initiative under EBOVAC 2 in which we evaluated safety and immunogenicity of a heterologous 2-dose Ad26, MVA regimen in healthy adults in Europe.

**Materials/methods:** In this randomized, multicentre trial, volunteers (aged  $\geq 18$  to  $\leq 65$ ) from UK and France received Ad26 (dose 1), MVA (dose 2) vaccination or placebo at different intervals: 28, 56 or 84 days.

Serious adverse events (AE) were assessed until the end of the study, AEs until 42 days post-dose 2, and solicited AEs until 7 days after each dose.

Binding antibodies measured by validated EBOV GP FANG ELISA assay with lower limit of quantification were assessed at different intervals up to one year post-dose 1 and reported as Geometric Mean Concentration (GMC).


**Results:** Healthy adult volunteers (N=421) were vaccinated with either an active regimen (N=375) or placebo (N=46).

The 2-dose Ad26, MVA vaccination was well tolerated with no safety signals identified. A single possibly vaccine-related SAE of a small fiber neuropathy was reported.

On Day 21 post-dose 2, irrespective of the vaccination interval  $>98\%$  of all subjects were responders (defined as 2.5x over a positive baseline or 2.5x over LLOQ). Higher GMCs were measured in subjects vaccinated with a 56 and 84 day interval (10131 and 11312 ELISA units/mL, respectively [95% CI: 8554; 11999 and 9072; 14106]) compared to the 28 day interval group (4627 ELISA units/mL, [95% CI: 3649; 5867]). One year post-dose 1, GMCs were 1205 and 1149 ELISA units/mL for the 0, 56 and 0, 28 regimens, respectively (Figure).

**Conclusions:** The Ad26, MVA vaccine regimens were found to be well tolerated and immunogenic. Binding antibody responses persisted at least up to one year post-dose 1. This study supports the further development of Ad26, MVA heterologous 2-dose vaccination for the prevention of Ebola Virus Disease.

**EBL2001: Binding Antibody Responses (EBOV GP FANG ELISA; ELISA units/mL)**



29<sup>TH</sup> ECCMID  
13-16 APRIL 2019 AMSTERDAM, NETHERLANDS  
POWERED BY M-ANAGE.COM

